Pozenel H
Arzneimittelforschung. 1978;28(3a):560-2.
In heart failure of the severity degrees II and III according to Friedberg's classification, administration of a daily maintenance dose of 0.5--0.75 mg of 14-hydroxy-3beta-[(4-O-methyl-alpha-L-rhamnopyranosyl)oxy]-14beta-bufa-4,20,22-trienolide (mesproscillarin, Clift) induces a cumulative blood level of 1--1.5 mg after 8--10 days. This level eliminates manifestations of heart failure both clinically and with regard to objective criteria. Increased heart rate returns to normal particularly in types of the tachycardiac atrial fibrillation. The frequency corrected QT-time is significantly reduced by about 30 ms. The relative heart volume decreases. The heart's work is increased by about 15%. No side effects are observed under this oral accumulative glycoside therapy.
根据弗里德伯格分类法，在II级和III级重度心力衰竭患者中，每日给予维持剂量0.5 - 0.75毫克的14 - 羟基 - 3β - [(4 - O - 甲基 - α - L - 鼠李吡喃糖基)氧基] - 14β - 蟾蜍 - 4,20,22 - 三烯醇内酯（甲丙基黄夹次苷，克利夫特），8 - 10天后血药浓度累积可达1 - 1.5毫克。该血药浓度在临床及客观标准方面均能消除心力衰竭的表现。心率加快恢复正常，尤其是在快速性心房颤动类型中。频率校正后的QT间期显著缩短约30毫秒。相对心脏容积减小。心脏做功增加约15%。在这种口服累积性糖苷治疗下未观察到副作用。
